AP3089A - The use of solid carrier particles to improve the processability of a pharmaceutical agent - Google Patents

The use of solid carrier particles to improve the processability of a pharmaceutical agent

Info

Publication number
AP3089A
AP3089A AP2010005429A AP2010005429A AP3089A AP 3089 A AP3089 A AP 3089A AP 2010005429 A AP2010005429 A AP 2010005429A AP 2010005429 A AP2010005429 A AP 2010005429A AP 3089 A AP3089 A AP 3089A
Authority
AP
ARIPO
Prior art keywords
processability
improve
pharmaceutical agent
carrier particles
solid carrier
Prior art date
Application number
AP2010005429A
Other languages
English (en)
Other versions
AP2010005429A0 (en
Inventor
Joanna M Koziara
Mark M Minning
Reza Oliyal
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40809930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2010005429A0 publication Critical patent/AP2010005429A0/en
Application granted granted Critical
Publication of AP3089A publication Critical patent/AP3089A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AP2010005429A 2008-05-02 2009-05-01 The use of solid carrier particles to improve the processability of a pharmaceutical agent AP3089A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4993508P 2008-05-02 2008-05-02
US15065509P 2009-02-06 2009-02-06
US15065209P 2009-02-06 2009-02-06
PCT/US2009/042607 WO2009135179A2 (en) 2008-05-02 2009-05-01 The use of solid carrier particles to improve the processability of a pharmaceutical agent

Publications (2)

Publication Number Publication Date
AP2010005429A0 AP2010005429A0 (en) 2010-10-31
AP3089A true AP3089A (en) 2015-01-31

Family

ID=40809930

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005429A AP3089A (en) 2008-05-02 2009-05-01 The use of solid carrier particles to improve the processability of a pharmaceutical agent

Country Status (27)

Country Link
US (1) US10039718B2 (pl)
EP (2) EP2296633B1 (pl)
JP (2) JP5722213B2 (pl)
KR (2) KR101659971B1 (pl)
CN (3) CN102123700A (pl)
AP (1) AP3089A (pl)
AU (3) AU2009242451C1 (pl)
BR (1) BRPI0911871A8 (pl)
CA (1) CA2720856C (pl)
CO (1) CO6321225A2 (pl)
CY (1) CY1117067T1 (pl)
DK (1) DK2296633T3 (pl)
EA (2) EA201591353A1 (pl)
EC (1) ECSP10010636A (pl)
ES (1) ES2553897T3 (pl)
HK (2) HK1153670A1 (pl)
HR (1) HRP20151357T1 (pl)
HU (1) HUE026380T2 (pl)
IL (2) IL208614A (pl)
MX (2) MX342377B (pl)
NZ (1) NZ588978A (pl)
PL (1) PL2296633T3 (pl)
PT (1) PT2296633E (pl)
SG (2) SG190618A1 (pl)
SI (1) SI2296633T1 (pl)
WO (1) WO2009135179A2 (pl)
ZA (1) ZA201008007B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
WO2009006199A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CN103356622A (zh) * 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
KR101659971B1 (ko) 2008-05-02 2016-09-26 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
SG10201912527XA (en) 2010-11-19 2020-02-27 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
PT2705027E (pt) * 2011-05-02 2015-09-11 Gilead Sciences Inc Sais sólido de amorfo de cobicistat (gs-9350)
RS56667B1 (sr) * 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Kombinovane formulacije darunavira
EP2744810B2 (en) 2011-08-16 2023-09-13 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
JP2015503624A (ja) 2012-01-12 2015-02-02 ギリアード サイエンシーズ， インコーポレイテッド 医薬組成物およびその調製方法
CA2862344A1 (en) 2012-02-03 2013-08-08 Gilead Science, Inc. Methods and intermediates for preparing pharmaceutical agents
US20150045366A1 (en) 2012-03-01 2015-02-12 Gilead Sciences, Inc. Spray dried formulations
CN104884063A (zh) * 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物
EP2938603A1 (en) * 2012-12-26 2015-11-04 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
DE102013205347A1 (de) * 2013-03-26 2014-10-02 Hilti Aktiengesellschaft Additiv-Zusammensetzung für Amin-Härter, deren Verwendung sowie diese enthaltende Amin-Härterzusammensetzung
CN103230403A (zh) * 2013-04-23 2013-08-07 苏州谷力生物科技有限公司 一种抗艾滋病毒的组合型药物片剂
JP2016538312A (ja) * 2013-11-29 2016-12-08 マイラン ラボラトリーズ リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ 非晶質のコビシスタットの固体分散体
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
WO2020122242A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 医薬組成物及びその製造方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113425702B (zh) * 2021-06-25 2022-08-26 中国药科大学 应用微流控技术制备纳米颗粒、制备方法及装置和用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
NL149711B (nl) 1970-06-15 1976-06-15 Sumitomo Chemical Co Werkwijze voor het vervaardigen van pillen, alsmede de aldus vervaardigde pillen.
CH586568A5 (pl) 1972-04-10 1977-04-15 Hoffmann La Roche
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2609958B1 (fr) 1987-01-27 1995-03-10 Honda Motor Co Ltd Dispositif de support pour roues arriere de motocyclettes
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
PT727419E (pt) 1992-12-29 2002-08-30 Abbott Lab Compostos intermediarios para a preparacao de inibidores da protease retroviral
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
JP4064476B2 (ja) * 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US20030035834A1 (en) * 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
RU2281757C2 (ru) * 2000-09-19 2006-08-20 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
NZ528886A (en) 2001-05-01 2005-04-29 Pfizer Prod Inc A dry process for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
JP4166580B2 (ja) 2001-05-18 2008-10-15 ロンザ ア−ゲ− ３−ヒドロキシ−３−メチル酪酸ナトリウムの固体組成物の製造方法
DE10126163A1 (de) * 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
JP4570357B2 (ja) 2001-07-06 2010-10-27 ライフサイクル ファーマ エー／エス 制御された凝集
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US6926906B2 (en) * 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
WO2004046115A1 (ja) * 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US7189416B2 (en) * 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
WO2004064846A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN1758901B (zh) * 2003-02-19 2010-04-28 生命周期药物公司 硅石或硅石衍生物作为吸附材料的用途
EP1601347A1 (en) 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) * 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
EP1675576A1 (en) * 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20060085686A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
EP1729766A1 (en) * 2004-03-01 2006-12-13 LEK Pharmaceuticals D.D. Pharmaceutical formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050238675A1 (en) * 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP5403912B2 (ja) 2004-06-28 2014-01-29 ベロクシス ファーマシューティカルズ エー／エス 液体製剤用担体としての多孔性錠剤
US20060009603A1 (en) * 2004-07-09 2006-01-12 David Young Fibrillation-resistant polypropylene tape
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2007039338A (ja) 2005-07-29 2007-02-15 Hirofumi Takeuchi シリカ系複合顆粒
DE602006015721D1 (de) 2005-12-14 2010-09-02 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
ATE510535T1 (de) 2006-01-05 2011-06-15 Lifecycle Pharma As Zerfallende befüllbare tabletten
CA2643054A1 (en) * 2006-02-20 2007-08-30 Asahi Breweries, Ltd. Granules, tablets and method of producing the same
MX2008012225A (es) 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
AU2007275860C1 (en) * 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008017867A2 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
WO2008029417A2 (en) * 2006-09-04 2008-03-13 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CN103356622A (zh) 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
WO2009006199A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
KR101659971B1 (ko) 2008-05-02 2016-09-26 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型

Also Published As

Publication number Publication date
JP2014012741A (ja) 2014-01-23
MX342377B (es) 2016-09-27
CO6321225A2 (es) 2011-09-20
PT2296633E (pt) 2015-12-04
HK1153670A1 (zh) 2012-04-05
AP2010005429A0 (en) 2010-10-31
HUE026380T2 (en) 2016-06-28
HK1215679A1 (zh) 2016-09-09
PL2296633T3 (pl) 2016-03-31
US20090324729A1 (en) 2009-12-31
CN104940937A (zh) 2015-09-30
CA2720856A1 (en) 2009-11-05
EA022950B1 (ru) 2016-03-31
DK2296633T3 (en) 2016-01-11
BRPI0911871A8 (pt) 2018-03-06
KR101784647B1 (ko) 2017-10-11
HRP20151357T1 (hr) 2016-01-29
KR101659971B1 (ko) 2016-09-26
CN102123700A (zh) 2011-07-13
EA201071173A1 (ru) 2011-08-30
ES2553897T3 (es) 2015-12-14
AU2009242451C1 (en) 2017-05-18
CN103479584A (zh) 2014-01-01
AU2014221210C1 (en) 2017-06-01
WO2009135179A2 (en) 2009-11-05
JP5722213B2 (ja) 2015-05-20
SG190618A1 (en) 2013-06-28
BRPI0911871A2 (pt) 2015-11-17
NZ588978A (en) 2013-01-25
EP2296633B1 (en) 2015-09-30
WO2009135179A3 (en) 2011-05-19
KR20110015581A (ko) 2011-02-16
CY1117067T1 (el) 2017-04-05
KR20160114728A (ko) 2016-10-05
EP3006032A1 (en) 2016-04-13
IL247417A0 (en) 2016-11-30
JP2011522790A (ja) 2011-08-04
ZA201008007B (en) 2011-10-26
SG10201609006WA (en) 2016-12-29
EP2296633A2 (en) 2011-03-23
JP5925171B2 (ja) 2016-05-25
IL208614A0 (en) 2010-12-30
EA201591353A1 (ru) 2016-01-29
SI2296633T1 (sl) 2015-11-30
ECSP10010636A (es) 2011-03-31
MX2010011963A (es) 2010-12-06
AU2016250470A1 (en) 2016-11-17
US10039718B2 (en) 2018-08-07
AU2014221210B2 (en) 2016-08-18
AU2009242451A1 (en) 2009-11-05
CA2720856C (en) 2016-02-02
IL208614A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IL247417A0 (en) Use of solid carrier particles to improve the ability to process pharmaceutical material
AU2014221210A1 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
GB0710369D0 (en) Improvements relating to perfume particles
PL2528930T3 (pl) 4`-azydonukleozydy jako związki przeciw hcv
ZA201108901B (en) Compounds useful as medicaments
ZA201106705B (en) Antiviral compounds and uses thereof
IL203051A (en) Use of alpha-ketoglutarate for drug preparation
GB0803124D0 (en) Improvements relating to benefit particles
HK1167857A1 (en) Antiviral compounds and uses thereof
HK1167592A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
PL2143429T4 (pl) Zastosowanie cylastatyny do zmniejszania nefrotoksyczności różnych związków
EP2179731A4 (en) EXTREMELY EASY TO BE TAKEN OF AMINO-ACIDIC MEDICINE GRANULATE
GB0902648D0 (en) Pharmaceutical compounds and compositions
PT2415463E (pt) Composição medicinal em partículas
HK1131039A1 (en) Pharmaceutical use of sophoricoside
HK1222553A1 (zh) 使用固體載體顆粒以提高藥劑的可加工性
GB0908317D0 (en) Pharmaceutical compounds and compositions
EP2514440A4 (en) TRANSDERMAL PREPARATION WITH A BASIC INFLAMMATORY MEDIUM
GB0701903D0 (en) Proximity of particles
GB0801171D0 (en) Proximity of particles
GB0902211D0 (en) Improvements relating to the entrapment of fine particles
GB0617257D0 (en) Improvements to use of component containers
GB0720032D0 (en) Improvements relating to the entrapment of fine particulates
GB0705750D0 (en) Improvement relating to the entrapment of fine particles
IL200640A0 (en) Caloguide"